ES2171458T3 - Compuestos aza espiro que actuan sobre el sistema colinergico con actividad agonista muscarinica. - Google Patents

Compuestos aza espiro que actuan sobre el sistema colinergico con actividad agonista muscarinica.

Info

Publication number
ES2171458T3
ES2171458T3 ES94921036T ES94921036T ES2171458T3 ES 2171458 T3 ES2171458 T3 ES 2171458T3 ES 94921036 T ES94921036 T ES 94921036T ES 94921036 T ES94921036 T ES 94921036T ES 2171458 T3 ES2171458 T3 ES 2171458T3
Authority
ES
Spain
Prior art keywords
compounds
espiro
agonist activity
colinergic
aza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94921036T
Other languages
English (en)
Inventor
Abraham Fisher
Yishai Karton
Daniele Marciano
Dov Barak
Haim Meshulam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
State of Israel
Original Assignee
State of Israel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by State of Israel filed Critical State of Israel
Application granted granted Critical
Publication of ES2171458T3 publication Critical patent/ES2171458T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS ESPIRO CON UNA ACTIVIDAD DEL SISTEMA NERVIOSO PERIFERICO Y CENTRAL, POR EJEMPLO, UNA ACTIVIDAD AGONISTA MUSCARINICA, CON LAS FORMULAS (I,II,III,IV,V,VI,VII,VIII Y IX) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, COMPUESTOS CUATERNARIOS QUE SE DERIVAN ESTRUCTURALMENTE DE DICHOS COMPUESTOS CON UN ATOMO DE NITROGENO TERCIARIO, ENANTIOMEROS Y SIMILARES, DONDE EL ANILLO A JUNTO EL ATOMO ESPIRO-CARBONO CONSTITUYE UN ANILLO DE PUENTE O NO, QUE CONTIENE UNO O DOS ATOMOS DE NITROGENO DE ANILLO Y TAMBIEN SE DEFINE EL VALOR DE CADA UNO DE LOS OTROS SIMBOLOS EN LAS FORMULAS.
ES94921036T 1993-07-20 1994-07-15 Compuestos aza espiro que actuan sobre el sistema colinergico con actividad agonista muscarinica. Expired - Lifetime ES2171458T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/094,855 US5534520A (en) 1990-04-10 1993-07-20 Spiro compounds containing five-membered rings

Publications (1)

Publication Number Publication Date
ES2171458T3 true ES2171458T3 (es) 2002-09-16

Family

ID=22247578

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94921036T Expired - Lifetime ES2171458T3 (es) 1993-07-20 1994-07-15 Compuestos aza espiro que actuan sobre el sistema colinergico con actividad agonista muscarinica.

Country Status (25)

Country Link
US (1) US5534520A (es)
EP (1) EP0711292B1 (es)
JP (1) JP3802050B2 (es)
KR (1) KR100341683B1 (es)
CN (1) CN1129942B (es)
AT (1) ATE212347T1 (es)
AU (1) AU696530B2 (es)
BG (1) BG62774B1 (es)
BR (1) BR9407088A (es)
CA (1) CA2167584C (es)
CZ (1) CZ295929B6 (es)
DE (1) DE69429724T2 (es)
DK (1) DK0711292T3 (es)
ES (1) ES2171458T3 (es)
FI (1) FI113777B (es)
HU (1) HU224638B1 (es)
IL (1) IL110340A (es)
NO (1) NO310075B1 (es)
NZ (1) NZ268637A (es)
PL (1) PL178931B1 (es)
PT (1) PT711292E (es)
RO (1) RO117851B1 (es)
RU (1) RU2129555C1 (es)
WO (1) WO1995003303A2 (es)
ZA (1) ZA945284B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
DK0618917T3 (da) * 1991-11-25 1997-10-13 American Home Prod 1Amino-2- (benzothiazolyl)methyl spiro isoquinolin-4(1h),3-pyrrolidin -1,2,3,5(2h)-tetroner og analoger deraf, der kan anvendes som aldosereduktaseinhibitorer.
JP3708962B2 (ja) * 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
WO1997011940A1 (en) 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
WO1997036868A1 (de) 1996-04-02 1997-10-09 Bayer Aktiengesellschaft Substituierte phenylketoenole als schädlingsbekämpfungsmittel und herbizide
EP0932401A1 (en) * 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US8048875B1 (en) * 1997-02-24 2011-11-01 S.L.A. Pharma Ag Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
CA2281755C (en) 1997-02-24 2006-11-07 Michael Albert Kamm Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
JP2002500652A (ja) 1997-05-30 2002-01-08 ニューロサーアチ・アクティーゼルスカブ スピロ−キヌクリジン誘導体、その製造方法及びその使用方法
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
AU763638B2 (en) * 1998-06-08 2003-07-31 Theravance Biopharma R&D Ip, Llc Muscarinic receptor antagonists
DE69905798T2 (de) 1998-06-12 2004-02-12 F. Hoffmann-La Roche Ag Di- oder Triazaspiro[4,5]decanderivate
ES2181336T3 (es) * 1998-06-12 2003-02-16 Hoffmann La Roche Espiro(piperidin-4,1'-pirrolo(3,4-c)pirrol).
US6353006B1 (en) 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
AU2001241056A1 (en) * 2000-03-09 2001-09-17 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs
AR035411A1 (es) * 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto
CN1516584A (zh) * 2001-04-18 2004-07-28 ŷ�����ǹɷ����޹�˾ 螺吡唑化合物
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
NZ533567A (en) * 2001-12-28 2007-06-29 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
DE10210195B4 (de) * 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
JP4584706B2 (ja) * 2002-05-03 2010-11-24 イスラエル インスティチュート フォー バイオロジカル リサーチ 中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物
RU2238071C2 (ru) * 2002-11-27 2004-10-20 Маркарян Эдуард Георгиевич Способ лечения пострадавших с черепно-мозговой травмой в ранний посттравматический период
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2006044497A2 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
EP1824853A4 (en) * 2004-12-09 2010-06-09 Virochem Pharma Inc NEW SPIROTROPAN COMPOUNDS AND METHOD FOR MODULATING THE ACTIVITY OF THE CHEMOKIN RECEPTOR
KR20070095310A (ko) * 2004-12-09 2007-09-28 바이로켐 파마 인코포레이티드 신규 스피로트로판 화합물 및 케모카인 수용체 활성의 조절방법
CA2615656A1 (en) * 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
ITMI20061279A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
WO2008030412A2 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US8293759B2 (en) * 2006-10-30 2012-10-23 Merck, Sharp & Dohme, Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
CN101631779A (zh) * 2006-12-12 2010-01-20 先灵公司 含有三环系统的天冬氨酰蛋白酶抑制剂
US7863291B2 (en) * 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US9034891B2 (en) 2009-01-26 2015-05-19 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
WO2010084499A2 (en) 2009-01-26 2010-07-29 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
JP5619907B2 (ja) * 2009-10-29 2014-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ α７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
BR112013026341A2 (pt) 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
EP2882428B1 (en) 2012-07-13 2019-01-16 Pain Therapeutics, Inc. A method of inhibiting tau phosphorylation
EP2908825B1 (en) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9489013B2 (en) 2012-12-20 2016-11-08 Merck Sharp & Dohme Corp. C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use
CN104870000A (zh) 2012-12-20 2015-08-26 默沙东公司 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途
US9580396B2 (en) 2012-12-21 2017-02-28 Merck Sharp & Dohme Corp. C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use
US9453034B2 (en) 2013-03-15 2016-09-27 Merck Sharp & Dohme Corp. C2-azaspiro iminothiazine dioxides as BACE inhibitors, compositions, and their use
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
EP3083575B1 (en) 2013-12-18 2021-11-03 Merck Sharp & Dohme Corp. C-6 spirocarbocyclic iminothiadiazine dioxides as bace inhibitors, compositions, and their use
EP3265466A4 (en) * 2015-03-06 2018-12-26 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
US10307409B2 (en) 2015-03-06 2019-06-04 Chase Pharmaceuticals Corporation Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
PL3523310T3 (pl) 2016-10-05 2022-08-29 Nsc Therapeutics Gmbh Krystaliczne polimorfy agonisty receptora muskarynowego acetylocholiny
WO2019180224A1 (en) 2018-03-22 2019-09-26 Nsc Therapeutics Gmbh Compounds and methods for use in the treatment of microglia-mediated disorders
EP4137496A4 (en) * 2020-05-12 2024-08-21 Beijing Greatway Pharmaceutical Technology Co., Ltd. COMPOUND FOR ADJUSTING NMDA RECEPTOR ACTIVITY, ASSOCIATED PHARMACEUTICAL COMPOSITION AND USE
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
JPS4917534B1 (es) * 1970-10-06 1974-05-01
BE790675A (fr) * 1971-10-29 1973-04-27 Science Union & Cie Nouveaux derives de l'oxa-1 diaza-3,8 spiro (4,5) decane
EP0189370A3 (de) * 1985-01-16 1988-01-27 Sandoz Ag Spiro-dioxolane, -dithiolane und -oxothiolane
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
EP0273659A1 (en) * 1986-12-27 1988-07-06 Takeda Chemical Industries, Ltd. Azaspiro compounds, their production and use
JPS63208590A (ja) * 1987-02-24 1988-08-30 Yamanouchi Pharmaceut Co Ltd ヘテロ環式スピロ化合物及びその製造法
IL87234A (en) * 1987-08-13 1992-02-16 Israel Inst Biolog Res Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them
ATE122353T1 (de) * 1987-10-05 1995-05-15 Yamanouchi Pharma Co Ltd Heterozyklische spiroverbindungen und ihre herstellung.
US4876260A (en) * 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
JPH02164882A (ja) * 1988-12-20 1990-06-25 Yamanouchi Pharmaceut Co Ltd スピロ化合物及びその中間体
JPH02247183A (ja) * 1989-03-20 1990-10-02 Yamanouchi Pharmaceut Co Ltd ヘテロ環スピロ化合物
YU150489A (sh) * 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
IL97726A (en) * 1990-04-10 1994-12-29 Israel Inst Biolog Res Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
TW201312B (en) * 1991-04-09 1993-03-01 Israel State Spiro bridged and unbridged heterocyclic compounds

Also Published As

Publication number Publication date
CN1129942B (zh) 2011-08-10
WO1995003303A2 (en) 1995-02-02
DE69429724T2 (de) 2002-08-29
DK0711292T3 (da) 2002-05-06
CA2167584C (en) 2006-10-24
NO960225L (no) 1996-03-12
CZ295929B6 (cs) 2005-12-14
CZ18296A3 (en) 1996-07-17
DE69429724D1 (de) 2002-03-14
KR100341683B1 (ko) 2002-11-30
FI113777B (fi) 2004-06-15
FI960238A0 (fi) 1996-01-17
PT711292E (pt) 2002-07-31
KR960703914A (ko) 1996-08-31
CA2167584A1 (en) 1995-02-02
JP3802050B2 (ja) 2006-07-26
AU7191594A (en) 1995-02-20
JPH09503491A (ja) 1997-04-08
NZ268637A (en) 1998-01-26
HUT74588A (en) 1997-01-28
WO1995003303A3 (en) 1995-03-02
RU2129555C1 (ru) 1999-04-27
NO310075B1 (no) 2001-05-14
EP0711292A1 (en) 1996-05-15
RO117851B1 (ro) 2002-08-30
EP0711292B1 (en) 2002-01-23
IL110340A0 (en) 1994-10-21
PL312684A1 (en) 1996-05-13
HU9600126D0 (en) 1996-03-28
BG100370A (bg) 1996-11-29
ZA945284B (en) 1995-10-12
AU696530B2 (en) 1998-09-10
FI960238A7 (fi) 1996-03-18
IL110340A (en) 1999-06-20
CN1129942A (zh) 1996-08-28
BR9407088A (pt) 1996-08-13
HU224638B1 (hu) 2005-12-28
ATE212347T1 (de) 2002-02-15
NO960225D0 (no) 1996-01-18
US5534520A (en) 1996-07-09
BG62774B1 (bg) 2000-07-31
PL178931B1 (pl) 2000-06-30

Similar Documents

Publication Publication Date Title
WO1995003303A3 (en) Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
ES2145318T3 (es) Imidazo(4,5-c)quinolin-aminas.
ES2081302T3 (es) Aril- y heteroaril-piperazinil carboxamidas que tienen actividad sobre el sistema nervioso central.
ES2188608T3 (es) Derivado de ester trifluorometilpirroloindol carboxilico y proceso para su produccion.
NO961687D0 (no) Nye (R)-5-karbamoyl-8-fluor-3-N,N-disubstituerte-amino-3,4-dihydro-2H-1-benzopyraner
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
ES8507534A1 (es) Procedimiento para la preparacion de derivados benzopiranicos
ES2164072T3 (es) Heterociclos no aromaticos que contienen nitrogeno sustituidos con bencilamino.
ES2108727T3 (es) Derivados de triazolopirimidina con actividad fungicida.
ES2106766T3 (es) Lentes oftalmicas multifocales difractivas.
AR025752A1 (es) Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
ES2075350T3 (es) Compuestos heterociclicos antiemeticos y supresores de la migraña, y composiciones farmaceuticas que los contienen.
ES2141631T3 (es) Estabilizacion del hidrocloruro de naloxon.
ES2067874T3 (es) Derivados de acetamida.
CO4900053A1 (es) Derivados de sulfonamida y -n-(4-aril-tiazol-2-il) y su uso
ES2164088T3 (es) Antagonistas de la sustancia p para el tratamiento de la emesis.
ES2163506T3 (es) Derivados de bencimidazolona con actividad dopaminergica central.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AR021714A1 (es) Nuevos compuestos biciclicos.
ES2054975T3 (es) Composiciones antimalaricas que emplean quinidina, artemisinina y sus derivados.
ES2147427T3 (es) Aminas ciclicas n-sustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
DE3752109D1 (de) Entzündungshemmende Mittel
ES2060709T3 (es) Derivados de piridilo y pirimidilo.
MX9204342A (es) Indoles.
DK0590150T3 (da) (-)-(S)-2,8-dimethyl-3-methylen-1-oxa-8-azaspiro[4,5]decan-L-tartrat

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 711292

Country of ref document: ES